メタボリックシンドロームの世界市場レポート 2025年

メタボリックシンドローム市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.4％で1,206億9,000万米ドルに成長します。予測期間中の成長は、日常生活におけるストレスレベルの上昇、ヘルスケアに対する意識の高まり、高度な診断ツールに対する需要の高まり、代謝性疾患の診断検査件数の増加、医療保険適用範囲の拡大などに起因すると考えられます。予測期間における主な動向としては、医療技術の発展、代謝健康モニタリングの強化、人工知能の統合、デジタル健康ツールの採用、スマートな摂取可能錠剤の開発などが挙げられます。

生活習慣病の有病率の上昇は、代謝検査市場の成長を促進すると予想されます。生活習慣病とは、遺伝的要因や感染要因ではなく、主に不健康な習慣や行動によって引き起こされる健康状態のことです。一般的な例としては、肥満、がん、2型糖尿病、骨粗鬆症、精神疾患などがあります。これらの疾患の罹患率の増加は、座りがちなライフスタイル、不健康な食生活、ストレスレベルの上昇、タバコやアルコールの蔓延に起因しています。メタボリックシンドロームは、慢性炎症、代謝機能の低下、心血管リスクの上昇を促進し、生活習慣病の悪化に重要な役割を果たしています。例えば、英国の政府機関であるNational Health Service Englandによると、非糖尿病性高血糖（糖尿病予備軍）と診断される人の数は、2022年の3,065,825例から2023年には3,615,330例へと18％増加しています。その結果、生活習慣病の有病率の増加がメタボリック検査市場の拡大に拍車をかけています。

メタボリックシンドローム市場の主要企業は、疾病管理、治療、予防を改善するために、臨床的裏付けのあるプロバイオティクス・ソリューションなどの技術革新に注力しています。臨床的裏付けのあるプロバイオティクス・ソリューションは、その健康上の利点と安全性を検証するために厳格な臨床試験を受けています。例えば、2024年10月、米国を拠点とする臨床的に証明された生物製剤のメーカーであるProbi USA社は、ラクチプランティバシラス・プランタラム299v株（LP299V株）とラクティカゼイバシラス・パラカゼイ8700,2株（L. Paracasei 8700,2株）の2株を組み合わせたプロバイオティクス製品「メタボリックヘルス」を発売しました。LP299Vは、コレステロール値、炎症、血管機能を改善することで心臓血管の健康をサポートし、230以上の論文と8つの臨床試験がその有効性を裏付けています。L.パラカゼイ8700,2（L.Paracasei 8700,2）は、30以上の論文に裏付けられ、血圧調整、コレステロール管理、体重管理をサポートします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界メタボリックシンドロームPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のメタボリックシンドローム市場：成長率分析
• 世界のメタボリックシンドローム市場の実績：規模と成長, 2019-2024
• 世界のメタボリックシンドローム市場の予測：規模と成長, 2024-2029, 2034F
• 世界メタボリックシンドローム総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のメタボリックシンドローム市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ1メタボリックシンドローム
• タイプ2メタボリックシンドローム
• タイプ3メタボリックシンドローム
• 世界のメタボリックシンドローム市場リスク要因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肥満
• インスリン抵抗性
• 高血圧
• 高コレステロール
• 世界のメタボリックシンドローム市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• ライフスタイルの変化
• その他の治療法
• 世界のメタボリックシンドローム市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のメタボリックシンドローム市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界のメタボリックシンドローム市場1型メタボリックシンドロームのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリン抵抗性症候群
• 腹部肥満症候群
• 高血糖症候群
• 世界のメタボリックシンドローム市場2型メタボリックシンドロームのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧症候群
• 脂質異常症症候群
• 低HDLコレステロール症候群
• 世界のメタボリックシンドローム市場、タイプ3メタボリックシンドロームのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動脈硬化性心血管疾患症候群
• 非アルコール性脂肪性肝疾患症候群
• 慢性炎症症候群

第7章 地域別・国別分析

• 世界のメタボリックシンドローム市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のメタボリックシンドローム市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• メタボリックシンドローム市場：競合情勢
• メタボリックシンドローム市場：企業プロファイル
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• AstraZeneca PLC
• Adocia
• Biocon Ltd.
• Bristol-Myers Squibb Company
• Cipla Limited
• Herbalife International of America Inc.
• Abbott Laboratories
• Shaklee Corporation
• Johnson & Johnson Private Limited
• Medtronic plc
• Apollo
• WW International Inc.
• Jenny Craig
• DSM

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• メタボリックシンドローム市場2029：新たな機会を提供する国
• メタボリックシンドローム市場2029：新たな機会を提供するセグメント
• メタボリックシンドローム市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metabolic syndrome is a collection of risk factors that increase the likelihood of developing heart disease, stroke, and type 2 diabetes. It is commonly associated with poor lifestyle choices, including unhealthy eating habits, lack of physical activity, and obesity. Treatment primarily focuses on lifestyle modifications, such as dietary changes, regular exercise, and medications to manage specific risk factors.

The primary types of metabolic syndrome include type 1, type 2, and type 3 metabolic syndrome. Type 1 metabolic syndrome is a rare metabolic disorder, often linked to genetic or autoimmune factors, that contributes to insulin resistance, obesity, and other cardiovascular risks. Treatments target various risk factors, including obesity, insulin resistance, high blood pressure, and high cholesterol. Management options include medications, lifestyle modifications, and other therapeutic approaches. Treatment is administered through oral, parenteral, and other routes and is utilized by various end users, such as hospitals, home care, and specialty centers.

The metabolic syndrome market research report is one of a series of new reports from The Business Research Company that provides metabolic syndrome market statistics, including metabolic syndrome industry global market size, regional shares, competitors with a metabolic syndrome market share, detailed metabolic syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic syndrome industry. This metabolic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic syndrome market size has grown strongly in recent years. It will grow from $84.03 billion in 2024 to $90.60 billion in 2025at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to sedentary work environments, the expansion of nutraceuticals and functional foods, rising consumer demand for natural products, increasing clinical research and trials, and advancements in healthcare digitalization.

The metabolic syndrome market size is expected to see strong growth in the next few years. It will grow to $120.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to rising stress levels in daily life, increasing healthcare awareness, growing demand for advanced diagnostic tools, a higher number of diagnostic tests for metabolic conditions, and expanding healthcare insurance coverage. Key trends in the forecast period include advancements in medical technology, enhanced metabolic health monitoring, the integration of artificial intelligence, the adoption of digital health tools, and the development of smart ingestible pills.

The rising prevalence of lifestyle diseases is expected to drive growth in the metabolic testing market. Lifestyle diseases are health conditions primarily caused by unhealthy habits and behaviors rather than genetic or infectious factors. Common examples include obesity, cancer, type 2 diabetes, osteoporosis, and mental health disorders. The increasing incidence of these conditions is attributed to sedentary lifestyles, unhealthy diets, rising stress levels, and the widespread use of tobacco and alcohol. Metabolic syndrome plays a crucial role in worsening lifestyle diseases by promoting chronic inflammation, impaired metabolic functions, and heightened cardiovascular risks. For example, according to the National Health Service England, a UK-based government department, the number of individuals diagnosed with non-diabetic hyperglycemia (pre-diabetes) increased by 18% from 3,065,825 cases in 2022 to 3,615,330 cases in 2023. As a result, the growing prevalence of lifestyle diseases is fueling the expansion of the metabolic testing market.

Leading companies in the metabolic syndrome market are focusing on technological innovations, such as clinically supported probiotic solutions, to improve disease management, treatment, and prevention. Clinically supported probiotic solutions undergo rigorous clinical testing to validate their health benefits and safety. For instance, in October 2024, Probi USA, a US-based manufacturer of clinically proven biotics, launched "Metabolic Health," a probiotic product combining two strains that include Lactiplantibacillus plantarum 299v (LP299V) and Lacticaseibacillus paracasei 8700,2 (L. Paracasei 8700,2). LP299V supports cardiovascular health by improving cholesterol levels, inflammation, and blood vessel function, with over 230 publications and eight clinical trials backing its efficacy. L. Paracasei 8700,2, supported by over 30 publications, aids in blood pressure regulation, cholesterol management, and weight control.

In August 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Inversago Pharma for an undisclosed amount. This acquisition strengthens Novo Nordisk's clinical pipeline for obesity and related disorders by investigating Inversago's lead drug, INV-202, as a potential treatment for obesity and its associated complications. Inversago Pharma Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in therapies for metabolic and fibrotic diseases.

Major players in the metabolic syndrome market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KGaA, Amgen Inc., AstraZeneca PLC, Adocia, Biocon Ltd., Bristol-Myers Squibb Company, Cipla Limited, Herbalife International of America Inc., Abbott Laboratories, Shaklee Corporation, Johnson & Johnson Private Limited, Medtronic plc, Apollo, WW International Inc., Jenny Craig, DSM, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche AG, Merck & Co. Inc.

North America was the largest region in the metabolic syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metabolic syndrome market consists of revenues earned by entities by providing services such medical management, nutrition counseling, physical activity programs, and insulin resistance management. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic syndrome market also includes sales of risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolic Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolic syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 Metabolic Syndrome; Type 2 Metabolic Syndrome; Type 3 Metabolic Syndrome
• 2) By Risk Factors: Obesity; Insulin Resistance; High Blood Pressure; High Cholesterol
• 3) By Treatment: Medication; Lifestyle Changes; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 5) By End User: Hospitals; Homecare; Specialty Centres; Other End Users
• Subsegments:
• 1) By Type 1 Metabolic Syndrome: Insulin Resistance Syndrome; Abdominal Obesity Syndrome; Hyperglycemia Syndrome
• 2) By Type 2 Metabolic Syndrome: Elevated Blood Pressure Syndrome; Dyslipidemia Syndrome; Low HDL Cholesterol Syndrome
• 3) By Type 3 Metabolic Syndrome: Atherosclerotic Cardiovascular Disease Syndrome; Non-Alcoholic Fatty Liver Disease Syndrome; Chronic Inflammation Syndrome
• Companies Mentioned: Novo Nordisk A/S; Sanofi S.A.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metabolic Syndrome Market Characteristics

3. Metabolic Syndrome Market Trends And Strategies

4. Metabolic Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metabolic Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metabolic Syndrome Market Growth Rate Analysis
• 5.4. Global Metabolic Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metabolic Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metabolic Syndrome Total Addressable Market (TAM)

6. Metabolic Syndrome Market Segmentation

• 6.1. Global Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Metabolic Syndrome
• Type 2 Metabolic Syndrome
• Type 3 Metabolic Syndrome
• 6.2. Global Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obesity
• Insulin Resistance
• High Blood Pressure
• High Cholesterol
• 6.3. Global Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Lifestyle Changes
• Other Treatments
• 6.4. Global Metabolic Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.5. Global Metabolic Syndrome Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centres
• Other End Users
• 6.6. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 1 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Resistance Syndrome
• Abdominal Obesity Syndrome
• Hyperglycemia Syndrome
• 6.7. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 2 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Elevated Blood Pressure Syndrome
• Dyslipidemia Syndrome
• Low HDL Cholesterol Syndrome
• 6.8. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 3 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atherosclerotic Cardiovascular Disease Syndrome
• Non-Alcoholic Fatty Liver Disease Syndrome
• Chronic Inflammation Syndrome

7. Metabolic Syndrome Market Regional And Country Analysis

• 7.1. Global Metabolic Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metabolic Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Syndrome Market

• 8.1. Asia-Pacific Metabolic Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Syndrome Market

• 9.1. China Metabolic Syndrome Market Overview
• 9.2. China Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Syndrome Market

• 10.1. India Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Syndrome Market

• 11.1. Japan Metabolic Syndrome Market Overview
• 11.2. Japan Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Syndrome Market

• 12.1. Australia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Syndrome Market

• 13.1. Indonesia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Syndrome Market

• 14.1. South Korea Metabolic Syndrome Market Overview
• 14.2. South Korea Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Syndrome Market

• 15.1. Western Europe Metabolic Syndrome Market Overview
• 15.2. Western Europe Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Syndrome Market

• 16.1. UK Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Syndrome Market

• 17.1. Germany Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Syndrome Market

• 18.1. France Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Syndrome Market

• 19.1. Italy Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Syndrome Market

• 20.1. Spain Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Syndrome Market

• 21.1. Eastern Europe Metabolic Syndrome Market Overview
• 21.2. Eastern Europe Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Syndrome Market

• 22.1. Russia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Syndrome Market

• 23.1. North America Metabolic Syndrome Market Overview
• 23.2. North America Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Syndrome Market

• 24.1. USA Metabolic Syndrome Market Overview
• 24.2. USA Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Syndrome Market

• 25.1. Canada Metabolic Syndrome Market Overview
• 25.2. Canada Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Syndrome Market

• 26.1. South America Metabolic Syndrome Market Overview
• 26.2. South America Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Syndrome Market

• 27.1. Brazil Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Syndrome Market

• 28.1. Middle East Metabolic Syndrome Market Overview
• 28.2. Middle East Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Syndrome Market

• 29.1. Africa Metabolic Syndrome Market Overview
• 29.2. Africa Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Metabolic Syndrome Market Competitive Landscape
• 30.2. Metabolic Syndrome Market Company Profiles
  • 30.2.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Syndrome Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. AstraZeneca PLC
• 31.3. Adocia
• 31.4. Biocon Ltd.
• 31.5. Bristol-Myers Squibb Company
• 31.6. Cipla Limited
• 31.7. Herbalife International of America Inc.
• 31.8. Abbott Laboratories
• 31.9. Shaklee Corporation
• 31.10. Johnson & Johnson Private Limited
• 31.11. Medtronic plc
• 31.12. Apollo
• 31.13. WW International Inc.
• 31.14. Jenny Craig
• 31.15. DSM

32. Global Metabolic Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Syndrome Market

34. Recent Developments In The Metabolic Syndrome Market

35. Metabolic Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Metabolic Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metabolic Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metabolic Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer